Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03)

Table 3 Treatment response and oncological outcome

Patient	Tumor site, histology and size	Sunitinib dose	RT dose	Resection margin	RECIST	% non-viable tissue	Follow-up status (and time), events (months after ED)
1	lower extremity, myxofibrosarcoma, 11 cm	25	50.4	R0	stable disease	30 %	NED (29mo), LR resected (19 mo)
2	lower extremity, dediff. lipo, 8 cm	25	50.4	R0	stable disease	95 %	AWD (36 mo), Soft tissue mets (15 mo)
3	Retroperitoneal, dediff. lipo, 15 cm	25	50.4	R1	stable disease	75 %	NED (28 mo)
4	Retroperitoneal, dediff. lipo, 12 cm	25	50.4	R1	stable disease	20 %	NED (11 mo)
5	Retroperitoneal, undiff. pleomorphic sarcoma, 14 cm	25	50.4	R2 (primary Tumor R0)	progressive disease (locally and mets)	70 %	DOD (9 mo), Liver mets at surgery
6	Groin, Dediff. lipo, 20 cm	25	50.4	R0	stable disease	30 %	NED (24 mo)
7	Retroperitoneal, myxoidlipo, 5 cm	37.5	50.4	R0	partial response	50 %	NED (20 mo)
8	lower extremity, synovial sarcoma, 8 cm	37.5	50.4	R0	stabledisease	100 %	AWD (23 mo), Lung mets (15 mo)
9	chest wall, undiff. pleomorphic sarcoma, 5 cm	37.5	50.4	R0	stabledisease	100 %	NED (13 mo)

ISSN: 1748-717X